A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Inclusion Criteria: * Postmenopausal female participants * Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²) Exclusion Criteria: * Have an unstable disease or a disease constituting a risk when taking the study intervention. * Have significant renal insufficiency * Have an important gastro-esophageal reflux disease, pyloric stenosis, gastroparesis or a history of gastric bypass surgery. * Have a history or presence of chronic or idiopathic acute pancreatitis. * Have a history of severe clinically significant multiple or severe drug allergies. * Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2 * Have had any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the cervix that have been resected with no evidence of metastatic disease for 3 years * Have any form of diabetes mellitus other than type 2 * Have type 2 diabetes with HbA1c greater than or equal to 10% at screening * Have received an oral or transdermal patch hormone replacement therapy (HRT) within the last 1 month prior to screening or depot injectable HRT within the last 6 months * Have received any investigational drug within the last month or 5 half-lives of this drug, whichever is longer, prior to screening. If the half-life of the previous investigational drug is unknown, the washout period should be at least 3 months before screening * Show evidence of HIV infection or positive HIV antibodies * Have evidence of, or test positive for, anti-hepatitis C virus antibody unless a confirmatory test for hepatitis C virus RNA is negative * Test positive for hepatitis B surface antigen. In case a hepatitis B virus DNA test was also performed recently and is positive, the participant should be excluded independently of the hepatitis B surface antigen test result. The hepatitis B core antibody test is not used to assess eligibility * Have acute or chronic hepatitis, or signs and symptoms of any other liver disease, or with significant abnormalities in laboratory liver tests * Have a fasting triglyceride level greater than 500 mg/dL at screening * Used any nicotine product including tobacco or nicotine replacement products within 1 month prior to screening or a positive cotinine test at screening. Are unable or unwilling to refrain from using such products during the study * Have donated at least 450 mL of blood within 8 weeks before screening or intend to donate blood during the study